| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
ONC212 (ONC-212; ONC 212), a fluorinated-ONC201 analog, is a novel, potent and selective agonist of GPR132 with anticancer activity. It exhibits strong in vivo efficacy against hepatocellular cancer and melanoma models.
| Targets |
GPR132; ONC212 is a selective agonist of GPR132 (G protein-coupled receptor 132) [1]
Additionally, it activates mitochondrial caseinolytic protease P (ClpP), leading to selective cancer cell death [4] |
|---|---|
| ln Vitro |
ONC212 exhibits potent antiproliferative effects in pancreatic cancer cell lines, with GI50 values ranging from 0.1 to 0.4 μM, which is at least 10-fold more potent than ONC201 [1]
In AML cell lines (OCI-AML3, MOLM13), ONC212 induces apoptosis with ED50 values of 141.0 nM and 105.7 nM, respectively [2] It triggers MCL1 degradation via NOXA upregulation and activates the AKT/NOX4/HuR/ATF4 pathway in AML U937 and HL-60 cells [2] In HeLa and A549 cells, ONC212 induces caspase-3 activation independently of mitochondrial membrane potential loss (ΔΨm) or cytochrome c release [4] ONC212 has at least ten times the potency of ONC201 compared to ONC212, and it exhibits an anti-proliferative effect in a wide panel of pancreatic cancer cell lines. In susceptible pancreatic cancer cell lines, ONC212 induces apoptosis earlier and at lower concentrations than ONC201[1]. On mantle cell lymphoma (MCL) and acute myeloid leukemia (AML) cell lines, ONC212 has strong and noticeable apoptogenic effects (e.g., ED50s of 141.0 nM in p53 wild-type OCI-AML3 cells, 105.7 nM in MOLM13 cells, and 265.2 nM in p53-null JeKo-1 cell lines). ONC212 takes longer than 36 hours to begin inducing apoptosis in OCI-AML3 cells, according to time course analysis of apoptosis[2]. Significantly, ONC212 causes cell cycle arrest and/or Sub-G1 apoptotic cells[4]. |
| ln Vivo |
ONC212 exhibits increased efficacy in melanoma and hepatocellular carcinoma xenograft models[1]. In mice, ONC212 exhibits a broad therapeutic window, a satisfactory PK profile, and oral well-tolerance at effective doses for both triple negative breast cancer and colon cancer[3]. ONC212 shows fast activity kinetics. ONC212 has a slightly shorter half-life than ONC201, with a Cmax of 1.4 mg/mL, a T1/2 of 4.3 hours, and a clearance from the blood at 12 hours. Despite systemic clearance, it has a sustained pharmacodynamic effect. In a human melanoma xenograft and hepatocellular model, oral ONC212 exhibits strong anti-tumor efficacy. While ONC212 only inhibits invasion of tumor cells, ONC206 and ONC201 both inhibit invasion and migration[4].
Oral administration of ONC212 (50 mg/kg, biweekly) significantly suppresses AML progression and extends median survival from 43 to 49 days (+14%) in mice [2] In melanoma and hepatocellular carcinoma xenograft models, ONC212 shows improved efficacy with a wide therapeutic window and no toxicity at effective doses [1] In GBM models, ONC212 inhibits c-Myc, leading to metabolic reprogramming and tumor cell apoptosis [3] |
| Cell Assay |
Oral administration of ONC212 (50 mg/kg, biweekly) significantly suppresses AML progression and extends median survival from 43 to 49 days (+14%) in mice [2]
In melanoma and hepatocellular carcinoma xenograft models, ONC212 shows improved efficacy with a wide therapeutic window and no toxicity at effective doses [1] In GBM models, ONC212 inhibits c-Myc, leading to metabolic reprogramming and tumor cell apoptosis [3] In assays for colony formation, 0.2 × 106 cells are seeded per well in a 6-well plate and treated with the appropriate doses of ONC201 or ONC212. After 72 hours of treatment, 500 cells from each treatment group are taken out and plated in triplicate in drug-free media to initiate the colony-forming process. On Day 10, colonies are stained with 0.25% crystal violet, counted, photographed, and reported as the number of colonies ± SEM. |
| Animal Protocol |
In AML xenograft studies, mice were dosed orally with ONC212 (50 mg/kg in 10% DMSO, 20% Kolliphor EL, 70% PBS) biweekly until tumor regression was observed [2]
For GBM models, ONC212 was administered weekly (50 mg/kg) to assess tumor growth inhibition and survival prolongation [3] In this study, female athymic nu/nu mice aged six to seven weeks are employed. TSubcutaneous injection of 50 μL of PBS mixed with 50 μL of Matrigel, containing 3 to 5×106 luciferase-expressing cells, is performed into the mice's back flanks. The indicated control or treatment groups are randomly assigned to mice once the tumor volume reaches an average of 100 to 150 cm3. By oral gavage, ONC201 and ONC212 are administered in a solution containing 10% DMSO, 20% Kolliphor®EL, and 70% PBS. Employing a digital caliper, the tumors' length (L) and width (W) are measured one or two times per week, and the tumor's volume is computed. To keep an eye out for indications of drug toxicity, mice are also weighed once a week [2]. |
| ADME/Pharmacokinetics |
ONC212 has a plasma half-life (T1/2) of 4.3 h, with a Cmax of 1.4 μg/mL after oral administration in mice [1]
It exhibits rapid blood clearance (12 h) but prolonged pharmacodynamic effects despite systemic elimination [4] |
| Toxicity/Toxicokinetics |
ONC212 is well-tolerated up to 250 mg/kg in mice, but 300 mg/kg causes splenic damage and elevated liver enzymes [1]
|
| References | |
| Additional Infomation |
ONC212 is a fluorinated derivative of ONC201 with enhanced potency and broader anticancer activity [1]
It synergizes with YM155 in AML by upregulating SLC35F2 and promoting NOXA-dependent MCL1 degradation [2] |
| Molecular Formula |
C24H23F3N4O
|
|---|---|
| Molecular Weight |
440.460835695267
|
| Exact Mass |
440.18
|
| Elemental Analysis |
C, 65.44; H, 5.26; F, 12.94; N, 12.72; O, 3.63
|
| CAS # |
1807861-48-8
|
| Related CAS # |
1807861-48-8
|
| PubChem CID |
124085867
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.8
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
32
|
| Complexity |
779
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1C=CC(=CC=1)CN1C(C2CN(CC3C=CC=CC=3)CCC=2N2CCN=C21)=O)(F)F
|
| InChi Key |
DFULPGUTXZTYKA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H23F3N4O/c25-24(26,27)19-8-6-18(7-9-19)15-31-22(32)20-16-29(14-17-4-2-1-3-5-17)12-10-21(20)30-13-11-28-23(30)31/h1-9H,10-16H2
|
| Chemical Name |
11-benzyl-7-[[4-(trifluoromethyl)phenyl]methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one
|
| Synonyms |
ONC 212; ONC-212; 11-Benzyl-7-[[4-(trifluoromethyl)phenyl]methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one; 11-benzyl-7-((4-(trifluoromethyl)phenyl)methyl)-2,5,7,11-tetrazatricyclo(7.4.0.02,6)trideca-1(9),5-dien-8-one; 1807861-48-8; 2,4,6,7,8,9-Hexahydro-7-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]methyl]imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one; 7-Benzyl-4-(4-(trifluoromethyl)benzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one; orb1299855; ONC212
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50~88 mg/mL (113.5~199.8 mM)
Ethanol: ~88 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2704 mL | 11.3518 mL | 22.7035 mL | |
| 5 mM | 0.4541 mL | 2.2704 mL | 4.5407 mL | |
| 10 mM | 0.2270 mL | 1.1352 mL | 2.2704 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
